Out of the laboratory and into the bathroom cabinet: designing and implementing clinical trials – Clinical Trials Paul Simmons Overview Once a drug candidate has been identified and undergone study in the laboratory and animals, it enters clinical trial, usually composed of 3 phases. Generally, as the drug candidate goes from phases 1 to 3, […]
Category: Research Initiative/Treatment Action!
Long-term nonprogressors: the study of HIV infection without progression to AIDS Thomas Gegeny Although the past decade has seen great strides in the treatment of HIV, much about the virus remains obscure. Drug development to date has mainly followed from research characterizing the life cycle of HIV (for instance, targeting viral reverse transcriptase or protease […]
Categories
LAMIVUDINE
LAMIVUDINE – Epivir Lamivudine tablets are film-coated, white, and diamond-shaped with the dosage “150” imprinted on one side and “GX CJ7” on the other side. This drug is also available in a flavored solution or in combination with zidovudine in a tablet formulation called “Combivir.” “The discovery of lamivudine’s hepatitis-suppressing potential will likely provide Glaxo […]
Letter From The Editor – insomnia in HIV patients Thomas Gegeny DEAR READER Everyone has trouble sleeping at one time or another. Anxiety the night before an important presentation or exam, stress about personal or financial matters, or even too much television or caffeine before bed can cause trouble sleeping. But insomnia is a different […]
Primary HIV infection case presentations The following cases illustrate the complexities involved in recognizing and correctly diagnosing primary HIV infection (PHI). Extensive lab work, but also thorough history taking, is required. Patient 1 was not recognized as suffering from PHI until after she was discharged from the hospital. Patient 2 was recognized with PHI, and […]
Letter from the editor – Brief Article Thomas Gegeny DEAR READER Sometimes taking a step back and looking at the “whole picture” helps us gain a better understanding of a situation. This issue of RITA! does exactly that by providing an overview of HIV therapeutic development. In a time when we are considering second and […]